NeuroOne Medical Technologies Co. (NASDAQ:NMTC) CFO Ronald W. Mcclurg Buys 200,000 Shares

NeuroOne Medical Technologies Co. (NASDAQ:NMTC) CFO Ronald W. Mcclurg bought 200,000 shares of the business’s stock in a transaction that occurred on Friday, April 4th. The shares were purchased at an average price of $0.50 per share, for a total transaction of $100,000.00. Following the completion of the purchase, the chief financial officer now directly owns 444,117 shares of the company’s stock, valued at approximately $222,058.50. This trade represents a 81.93 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink.

NeuroOne Medical Technologies Stock Up 2.3 %

NASDAQ NMTC opened at $0.44 on Wednesday. NeuroOne Medical Technologies Co. has a 52 week low of $0.41 and a 52 week high of $1.39. The firm has a 50 day moving average of $0.99 and a two-hundred day moving average of $0.93. The stock has a market capitalization of $13.58 million, a PE ratio of -1.69 and a beta of 0.61.

NeuroOne Medical Technologies (NASDAQ:NMTC) last posted its earnings results on Wednesday, February 12th. The company reported $0.06 EPS for the quarter. NeuroOne Medical Technologies had a negative return on equity of 270.70% and a negative net margin of 82.17%.

Institutional Investors Weigh In On NeuroOne Medical Technologies

Several hedge funds and other institutional investors have recently made changes to their positions in the business. XTX Topco Ltd purchased a new position in NeuroOne Medical Technologies in the third quarter valued at approximately $26,000. Jane Street Group LLC purchased a new position in NeuroOne Medical Technologies during the 4th quarter worth approximately $33,000. Finally, Geode Capital Management LLC increased its position in NeuroOne Medical Technologies by 9.8% during the fourth quarter. Geode Capital Management LLC now owns 311,659 shares of the company’s stock worth $257,000 after buying an additional 27,804 shares during the period. Institutional investors and hedge funds own 16.07% of the company’s stock.

About NeuroOne Medical Technologies

NeuroOne Medical Technologies Corporation, a developmental stage company, provides solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other related neurological disorders.